Carvolix continues its acceleration under the leadership of Anne Lange and with promising half-year results for 2026.

Carvolix, a medical technology company, announces the appointment of Anne Lange as Chair of its Board of Directors and its 2026 half-year results. This period is marked by commercial expansion, notably with the TAVIPILOT® software for which CE marking is in progress.

Kalios®, Carvolix's mitral ring, has demonstrated positive clinical results over three years, achieving its objectives without any adverse events. Financially, Carvolix has secured an additional €20 million through strategic partnerships, guaranteeing its resources until 2027. The company continues its development within the Euronext indices, strengthening its visibility in the financial markets.